708 studies found for:    trastuzumab
Show Display Options
RSS Create an RSS feed from your search for:
trastuzumab
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
3 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
4 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
5 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
6 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
7 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
8 Recruiting A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).
Condition: Brest Cancer
Interventions: Drug: Trastuzumab subcutaneous inyection vial;   Device: Trastuzumab subcutaneous device administration
9 Recruiting Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
10 Active, not recruiting Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: PF03512676;   Other: Correlative Studies
11 Active, not recruiting Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Trastuzumab
12 Terminated Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Condition: Metastatic Breast Cancer
Interventions: Drug: G-CSF;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: saline
13 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
14 Recruiting Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Conditions: Metastatic Breast Cancer;   Carcinomatous Meningitis
Intervention: Drug: Trastuzumab
15 Recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab
16 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
17 Recruiting NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Condition: HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab
Interventions: Drug: BKM120;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
18 Active, not recruiting A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: HKI-272;   Drug: Herceptin
19 Completed Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Condition: Advanced Cancers
Interventions: Drug: Pazopanib;   Drug: Lapatinib;   Drug: Trastuzumab (Herceptin®)
20 Completed 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years